Skip to main content
Midas Edge

Edgewise Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

EWTX$48.74+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity

(In thousands, except share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common Stock · ​ · Additional · ​ · Other Comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · Shares · Amount · Paid-In Capital · Loss · Deficit · Total
Balance as of December 31, 202263,257,376​$6​$492,665​$(1,355)​$(144,600)​$346,716
Exercise of stock options17,356​—​21​​—​—​21
Stock-based compensation—​—​3,837​​—​—​3,837
Other comprehensive income​—​—​—​​1,104​—​1,104
Net loss​—​—​—​​—​(22,838)​(22,838)
Balance as of March 31, 202363,274,732​$6​$496,523​$(251)​$(167,438)​$328,840
Exercise of stock options and vesting of restricted stock​135,326​​—​​31​​—​​—​​31
Purchase of common stock under employee stock purchase plan​48,874​​—​​338​​—​​—​​338
Stock-based compensation​—​​—​​4,011​​—​​—​​4,011
Other comprehensive loss​—​​—​​—​​(296)​​—​​(296)
Net loss​—​​—​​—​​—​​(21,469)​​(21,469)
Balance as of June 30, 2023​63,458,932​$6​$500,903​$(547)​$(188,907)​$311,455
Exercise of stock options​2,007​​—​​3​​—​​—​​3
Stock-based compensation​—​​—​​4,559​​—​​—​​4,559
Other comprehensive income​—​​—​​—​​123​​—​​123
Net loss​—​​—​​—​​—​​(25,713)​​(25,713)
Balance as of September 30, 2023​63,460,939​$6​$505,465​$(424)​$(214,620)​$290,427
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common Stock · ​ · Additional · ​ · Other Comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · Shares · Amount · Paid-In Capital · Income · Deficit · Total
Balance as of December 31, 2023​70,453,342​$7​$563,487​$99​$(244,763)​$318,830
Issuance of common stock, net of offering costs​22,450,206​​2​​238,797​​—​​—​​238,799
Exercise of stock options380,980​—​1,926​​—​—​1,926
Stock-based compensation—​—​4,871​​—​—​4,871
Other comprehensive loss—​—​—​​(960)​—​(960)
Net loss—​—​—​​—​(28,525)​(28,525)
Balance as of March 31, 202493,284,528​$9​$809,081​$(861)​$(273,288)​$534,941
Exercise of stock options and vesting of restricted stock​283,039​—​1,577​​—​—​1,577
Purchase of common stock under employee stock purchase plan​75,774​—​422​​—​—​422
Stock-based compensation​—​—​5,224​​—​—​5,224
Other comprehensive loss​—​—​—​​(193)​​—​​(193)
Net loss​—​—​—​​—​(31,497)​(31,497)
Balance as of June 30, 2024​93,643,341​$9​$816,304​$(1,054)​$(304,785)​$510,474
Exercise of stock options​765,570​​—​​3,547​​—​​—​​3,547
Stock-based compensation​—​​—​​6,880​​—​​—​​6,880
Other comprehensive income​—​​—​​—​​2,105​​—​​2,105
Net loss​—​​—​​—​​—​​(34,129)​​(34,129)
Balance as of September 30, 2024​94,408,911​$9​$826,731​$1,051​$(338,914)​$488,877
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.